Paper Details

  1. Home
  2. Paper Details

High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomiting.

Author: FalksonC I, FalksonG, FalksonH C

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Granisetron, a 5HT3 receptor antagonist, effectively reduced nausea and vomiting in patients undergoing highly emetogenic chemotherapy. The higher dose of 160 micrograms/kg was more effective than 40 micrograms/kg.
Paper Details　
Original Abstract of the Article :
Fifty six patients, with histologically confirmed cancer, who received highly emetogenic chemotherapy, were entered on a randomized double blind, low versus high dose, study of granisetron, a 5HT3 receptor antagonist. A single dose of intravenous granisetron protected the majority of patients from n...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF00198602

データ提供：米国国立医学図書館（NLM）

Granisetron: A Powerful Weapon Against Chemotherapy-Induced Nausea and Vomiting

Chemotherapy-induced nausea and vomiting (CINV) is a distressing side effect of cancer treatment. This study investigated the efficacy of granisetron, a 5HT3 receptor antagonist, in preventing CINV in patients receiving highly emetogenic chemotherapy. The researchers compared the effectiveness of two different doses of granisetron, a low dose and a high dose, in a randomized, double-blind study.

Dose-Dependent Efficacy of Granisetron in Preventing CINV

The study revealed that granisetron was highly effective in preventing CINV, with the higher dose (160 micrograms/kg) providing superior protection compared to the lower dose (40 micrograms/kg). These findings suggest that granisetron is a valuable tool for managing CINV and improving the quality of life for patients undergoing chemotherapy.

Easing the Burden of CINV: A Step Towards Improved Chemotherapy Tolerance

This study offers hope for patients experiencing the debilitating effects of CINV. The findings demonstrate the effectiveness of granisetron in reducing nausea and vomiting, contributing to a more comfortable and tolerable chemotherapy experience. Think of it as a cool desert breeze, offering relief from the harshness of CINV.

Dr. Camel's Conclusion

This study demonstrates the efficacy of granisetron in preventing CINV, particularly at a higher dose. The findings highlight the importance of appropriate dosing and emphasize the role of 5HT3 receptor antagonists in improving the quality of life for patients undergoing chemotherapy.

Date :
  1. Date Completed 1991-05-14
  2. Date Revised 2019-10-22
Further Info :

Pubmed ID

1964678

DOI: Digital Object Identifier

10.1007/BF00198602

Related Literature

Article Analysis
・Effects of granisetron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.